Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment

References

• Alvaro T, de la Cruz-Merino L, Henao-Carrasco F, et al. Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes. J Biomed Biotechnol. 2010;2010:Article ID 846872. DOI: 10.1155/2010/846872.
   PubMedGoogle Scholar
• Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–2433.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA. 1985;82:7439–7443.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79–88.
   PubMed Web of Science ®Google Scholar
• Sander B, de Jong D, Rosenwald A, et al. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg lymphoma biomarker consortium. Haematologica. 2014;99:715–725.
   PubMed Web of Science ®Google Scholar
• Fend F, Quintanilla-Martinez L. Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma. Haematologica 2014;99:599–602.
   PubMed Web of Science ®Google Scholar
• Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA. 2003;100:1926–1930.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Glas AM, Kersten MJ, Delahaye LJ, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood. 2005;105:301–307.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Immuno-histochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350–5357.
   PubMed Web of Science ®Google Scholar
• de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005;23:6358–6363.
   PubMed Web of Science ®Google Scholar
• Farinha P, Al-Tourah A, Gill K, et al. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood. 2010;115:289–295.
   PubMed Web of Science ®Google Scholar
• Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol. 2007;25:390–398.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957–2964.
   PubMed Web of Science ®Google Scholar
• Lee AM, Clear AJ, Calaminici M, et al. Number of CD4 + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24:5052–5059.
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica. 2009;94:70–77.
   PubMed Web of Science ®Google Scholar
• Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002;99:282–289.
   PubMed Web of Science ®Google Scholar
• Harjunpaa A, Taskinen M, Nykter M, et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol. 2006;135:33–42.
   PubMed Web of Science ®Google Scholar
• Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1–positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637–650.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Camacho FI, et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006;91:1605–1612.
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Goldman B, LeBlanc ML, et al. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a southwest oncology group study. Ann Oncol. 2010;21:1196–1202.
   PubMed Web of Science ®Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Leppa S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood. 2008;111:4664–4667.
   PubMed Web of Science ®Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13:5784–5789.
   PubMed Web of Science ®Google Scholar
• Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2008;26:440–446.
   PubMed Web of Science ®Google Scholar
• Chang KC, Huang X, Medeiros LJ, et al. Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma. J Pathol. 2003;201:404–412.
   PubMed Web of Science ®Google Scholar
• Shiozawa E, Yamochi-Onizuka T, Yamochi T, et al. Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract. 2003;199:293–302.
   PubMed Web of Science ®Google Scholar
• Thomazy VA, Vega F, Medeiros LJ, et al. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: tissue transglutaminase reveals coordinate regulation of multiple cell types. Am J Pathol. 2003;163:165–174.
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol. 2001;13:291–298.
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941–952.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Vasanthakumar A, Grigoriadis G. Modulating T regulatory cells in cancer: how close are we? Immunol Cell Biol. 2013;91:340–349.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27:1470–1476.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Rolver L, et al. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German low grade lymphoma study group. J Clin Oncol. 2007;25:3330–3336.
   PubMed Web of Science ®Google Scholar
• Luckey U, Schmidt T, Pfender N, et al. Crosstalk of regulatory T cells and tolerogenic dendritic cells prevents contact allergy in subjects with low zone tolerance. J Allergy Clin Immunol. 2012;130:781–797.
   PubMed Web of Science ®Google Scholar
• Cho WY, Choi HM, Lee SY, et al. The role of Tregs and CD11c(+) macrophages/dendritic cells in ischemic preconditioning of the kidney. Kidney Int. 2010;78:981–992.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25 + CD4 + regulatory T cells by antigen-processing dendritic cells. J Exp Med. 2003;198:235–247.
   PubMed Web of Science ®Google Scholar
• Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4 + CD25 + immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–440.
   PubMed Web of Science ®Google Scholar